| Title |
One-year outcomes of a conformable single-shot pulsed-field ablation catheter for the treatment of paroxysmal atrial fibrillation |
| Authors |
Reddy, Vivek Y ; Peichl, Petr ; Kautzner, Josef ; Anter, Elad ; Metzner, Andreas ; Koruth, Jacob ; Jais, Pierre ; Račkauskas, Gediminas ; Petru, Jan ; Funasako, Moritoshi ; Marinskis, Germanas ; Turagam, Mohit ; Aidietis, Audrius ; Selma, Jada M ; Nejedlo, Vojtech ; Kueffer, Fred ; Tarakji, Khaldoun G ; Natale, Andrea ; Neuzil, Petr |
| DOI |
10.1016/j.hrthm.2025.04.031 |
| Full Text |
|
| Is Part of |
Heart Rhythm.. New York : Elsevier Inc.. 2025, Early Access, p. [1-11].. ISSN 1547-5271. eISSN 1556-3871 |
| Keywords [eng] |
atrial fibrillation ; burden ; catheter ablation ; mapping ; pulsed-field ablation |
| Abstract [eng] |
Background: Most single-shot pulsed-field ablation (PFA) catheters require extensive repositioning for pulmonary vein isolation (PVI), posing a challenge for obtaining contiguous, durable lesions. Objective: To determine 1-year outcomes of a single-shot, all-in-one mapping and ablation PFA catheter for treating paroxysmal atrial fibrillation (PAF). Methods: After PVI with the large-lattice catheter with expandable tip (Sphere-360), follow-up included Holter monitoring at 180 and 365 days and scheduled/symptomatic trans-telephonic monitoring (TTM) or modeled insertable loop recorder (ILR) data. Efficacy outcomes were acute PVI and 12-month freedom from atrial arrhythmias (AA), after 90-day blanking. Optional invasive remapping at 75 days facilitated waveform refinement from PULSE1, PULSE2, to the optimized PULSE3. Results: At 3 centers, 100 PAF patients underwent PFA with PULSE1 (n = 30), PULSE2 (n = 20), or PULSE3 (n = 50). Procedure, left atrial dwell, and fluoroscopy times were 57.9 ± 20.6, 22.2 ± 11.8 and 6.8 ± 5.7 minutes, respectively. All 395 targeted PVs were acutely isolated, with a transpired PVI time of 11.5 ± 6.0 minutes, using 4.0 ± 1.3 lesions/PV. There were no primary safety events (serious device-related events within 7 days post-PFA). PVI durability with PULSE3 (n = 40) was 98% (per-vein) and 93% (per-patient). One-year freedom from AA recurrence was 82.0% (95% CI:73.0%–88.3%) overall, and 88.0% (95%CI, 75.2%–94.4%) for PULSE3 patients. Of the ILR sub-cohort (n = 15 PULSE3 patients), 3 patients (20%) had recurrences, with an AA burden reduction from 26% (baseline) to 1.6% (post-ablation). Conclusion: The large lattice PFA catheter was efficient, safe, and effective in treating PAF. The observed high PVI durability translated to clinical effectiveness, even in continuously monitored patients. |
| Published |
New York : Elsevier Inc |
| Type |
Journal article |
| Language |
English |
| Publication date |
2025 |
| CC license |
|
